EDAP Stock Overview
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EDAP TMS S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.13 |
| 52 Week High | US$12.23 |
| 52 Week Low | US$3.60 |
| Beta | 0.64 |
| 1 Month Change | -5.56% |
| 3 Month Change | 16.69% |
| 1 Year Change | -32.89% |
| 3 Year Change | -15.62% |
| 5 Year Change | 44.92% |
| Change since IPO | -16.12% |
Recent News & Updates
Recent updates
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Mar 22
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Mar 03It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
Jan 19Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
Aug 11Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?
Dec 19EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals
Nov 23EDAP TMS stock falls 7% aftermarket on proposed ADS offering
Sep 22EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M
Aug 24EDAP's Focal One Revenue Is Set To Accelerate
Aug 08Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?
Jul 19Acceleration At EDAP
Jan 11EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt
Jan 06The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot
Nov 25EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real
Sep 07EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO
Jun 15EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Apr 02Analysts Are Betting On EDAP TMS S.A. (NASDAQ:EDAP) With A Big Upgrade This Week
Jan 24
Treatment with EDAP's HIFU ultrasound benefits in prostate cancer patients, study shows
Jan 14New reimbursement rules for HIFU technology to favor EDAP TMS
Dec 09EDAP TMS S.A. EPS misses by $0.02, beats on revenue
Nov 18Shareholder Returns
| EDAP | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.1% | -4.4% | -3.7% |
| 1Y | -32.9% | -2.8% | 20.2% |
Return vs Industry: EDAP underperformed the US Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: EDAP underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| EDAP volatility | |
|---|---|
| EDAP Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EDAP's share price has been volatile over the past 3 months.
Volatility Over Time: EDAP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 307 | Ryan Rhodes | www.edap-tms.com |
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
EDAP TMS S.A. Fundamentals Summary
| EDAP fundamental statistics | |
|---|---|
| Market cap | US$264.55m |
| Earnings (TTM) | -US$22.54m |
| Revenue (TTM) | US$64.31m |
4.1x
P/S Ratio-11.7x
P/E RatioIs EDAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDAP income statement (TTM) | |
|---|---|
| Revenue | €60.42m |
| Cost of Revenue | €36.01m |
| Gross Profit | €24.41m |
| Other Expenses | €45.59m |
| Earnings | -€21.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 40.40% |
| Net Profit Margin | -35.05% |
| Debt/Equity Ratio | 10.7% |
How did EDAP perform over the long term?
See historical performance and comparison